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Exosomes Derived from Human Primed
Mesenchymal Stem Cells Induce Mitosis
and Potentiate Growth Factor Secretion
Oliver Yuan,1 Clayton Lin,1 Joseph Wagner,2 Joehleen A. Archard,1 Peter Deng,3
Julian Halmai,3 Gerhard Bauer,4 Kyle D. Fink,3 Brian Fury,4 Nicholas H. Perotti,4
Jon E. Walker,5 Kari Pollock,5 Michelle Apperson,3 Janelle Butters,3 Peter Belafsky,1
D. Gregory Farwell,1 Maggie Kuhn,1 Jan Nolta,5 and Johnathon D. Anderson1
Mesenchymal stem cells (MSCs) facilitate functional recovery in numerous animal models of inflammatory and
ischemic tissue-related diseases with a growing body of research suggesting that exosomes mediate many of
these therapeutic effects. It remains unclear, however, which types of proteins are packaged into exosomes
compared with the cells from which they are derived. In this study, using comprehensive proteomic analysis, we
demonstrated that human primed MSCs secrete exosomes (pMEX) that are packaged with markedly higher
fractions of specific protein subclasses compared with their cells of origin, indicating regulation of their
contents. Notably, we found that pMEX are also packaged with substantially elevated levels of extracellular-
associated proteins. Fibronectin was the most abundant protein detected, and data established that fibronectin
mediates the mitogenic properties of pMEX. In addition, treatment of SHSY5Y cells with pMEX induced the
secretion of growth factors known to possess mitogenic and neurotrophic properties. Taken together, our
comprehensive analysis indicates that pMEX are packaged with specific protein subtypes, which may provide a
molecular basis for their distinct functional properties.
Keywords: mesenchymal stem cells, exosomes, proteomics, HiRIEF LC-MS/MS, ischemic tissue, proliferation,
extracellular matrix, fibronectin
Introduction
Numerous preclinical studies have demonstrated thatmesenchymal stem cells (MSCs) hold promise as cell-
based therapeutics for the treatment of inflammation-associated
diseases [1–23]. Themolecular mechanisms underlyingMSCs’
therapeutic properties remain inadequately characterized. Most
published reports to date have focused on MSC-derived ca-
nonical secretory proteins as key drivers of functional re-
covery in animal models [24–30]. However, recent work
from our laboratory and others have demonstrated that small,
cellularly secreted vesicles called exosomes mediate much of
MSCs’ tissue healing effects, with administration of isolated
exosomes capable of recapitulating many of the therapeutic
effects observed via MSC transplantation [18,19,31–58].
Exosomes represent a recently characterized cell-to-cell
communication system that transport numerous factors
previously thought to be cell autonomous: nonsecretory
proteins, RNAs, lipids, and metabolites [57,59–62]. Pre-
vious reports have focused on the RNA content of exo-
somes; however, our group and others have observed
exosomal preps with substantially more protein content than
RNA content, suggesting that the protein contents of exo-
somes may warrant further investigation.
The majority of published reports to date that have in-
vestigated the secretome of MSCs have done so using ca-
nonical expansion of cell culture conditions. However, the
microenvironment experience by MSC postadministration
into animal models and patients is strikingly different, in-
cluding a substantial reduction in oxygen tension. Standard
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MSC culture conditions utilize an atmospheric oxygen ten-
sion of 20.95%, whereas various tissue compartments in the
body can range from 1% to 5% O2. In addition, MSCs are
generally culture using high levels of fetal bovine serum
(FBS), which contains an abundance of embryonic growth-
promoting factors. Such embryonic-associated paracrine and
endocrine signaling factors are present in much lower con-
centrations in most adult tissues. Consequently, we have
focused our efforts on understanding the secretome profile
of MSCs transiently exposed to a more in vivo-like culturing
system, using 1% O2 and serum deprivation to better model
a more clinically relevant microenvironment.
Previously, we demonstrated that MSCs primed with such
culture conditions increase expression of glycolytic, trophic,
and mitogenic proteins, which were also reflected in the
proteome of exosomes isolated from such primed MSCs
(pMEX) [31].
However, it is currently unclear whether the proteins
packaged into exosomes are done so in a stochastic manner or
whether such packaging is a more regulated cellular process.
The aim of this study was to assess whether pMEX are
broadly enriched for specific classes of proteins, as this re-
mains an outstanding question in the field. Toward this end,
we compared the proteomic profiles of pMSC and pMEX,
which revealed that pMEX are highly enriched with specific
subclassifications of proteins, including secretory and extra-
cellular matrix (ECM)-associated proteins. MSCs and their
derived exosomes have been shown promise in preclinical
studies for the treatment of diseases of the central nervous,
increasing the plasticity of the effect neuronal tissue. The
SHSY6Y cell line has been historically used for in vitro
neuronal assays, based on their ability to differentiate from a
progenitor cell phenotype to that of a mature neuronal phe-
notype. In this study, we demonstrated that pMEX are readily
taken up by such neuroblast-like cells (SHSY5Ys) within 1 h
of exposure and induce their cellular proliferation, as pre-
dicted based on the bioinformatic analysis of pMEXs pro-
teome. We further determined that the most abundant protein
packaged into pMEX was the ECM-associated protein, fi-
bronectin, which, in part, mediated pMEXs mitogenic prop-
erties in cells of central nervous system (CNS) lineage.
Materials and Methods
Cell culture and exosome isolation
Five fresh human bone marrow aspirates were pur-
chased from Lonza (Allendale, NJ). Human bone marrow
is withdrawn from bilateral punctures of the posterior iliac
crests of normal volunteers. Each donor is between the
ages of 18 and 45 years and tested by Lonza and found to
be nonreactive by an FDA-approved method for the
presence of HIV-I, hepatitis B virus, and hepatitis C virus.
After getting acceptable vital signs and hematology val-
ues, all donors are screened for general health and nega-
tive medical history for heart disease, kidney disease, liver
disease, cancer, epilepsy, and blood or bleeding disorders.
The Lonza Donor Program is currently approved, has been
approved for over 10 years, and is submitted for annual
approval by a commercial Institutional Review Board.
MSCs were isolated from each donor via the established
method of differential plastic adherence and use of MSC-
media and maintained as separate cell lines. MSCs were
isolated and then expanded by passing bone marrow as-
pirates through 90 mm pore cell strainers to isolate bone
spicules. The strained aspirates were then diluted with an
equal volume of phosphate-buffered saline (PBS) and
centrifuged over Ficoll (GE Healthcare, Waukesha, WI)
for 30min at 700g. Then, mononuclear cells and bone
spicules were plated in plastic tissue culture flasks, using
minimum essential media a (MEM-a) (HyClone Thermo
Scientific, Waltham, MA) supplemented with 10% pre-
mium select fetal bovine serum (FBS; Atlanta Biologicals,
Lawrenceville, GA) that had been prescreened for optimal
MSC growth. Following 2 days in culture, nonadherent
cells were removed via three PBS washes. After the sec-
ond passage, cells were expanded in 20% FBS in MEM-a,
1% l-Glutamine, and 1%Pen-Strep (MSC-media). Elig-
ibility criteria for future studies were MSC populations
that were 90% for the canonical MSC surface markers by
passage 3 (CD73, CD90, and CD105) as assessed by flow
cytometry evaluation using validated primary fluorochrome-
conjugated monoclonal antibodies. MSCs expanded and
cryopreserved until passages 6 before the initiation of use in
studies. For pMEX isolation, MSCs were thawed and spun
down (500g, 5min) in 15mL of full MSC media to eliminate
cryopreservation reagent, dimethyl sulfoxide. MSCs were re-
suspended in MSC media and plated at a seeding density of
500–1,000 cells/cm2 in 30mL of MSC media in T175 vented-
cap flasks. Once cells reached 70% confluency, MSC flasks
(*100·T175’s per exosome isolation) were washed three
times with 10mL of PBS and subsequently placed in Opti-
MEM without phenol red with 1% l-Glut (IC) (Life Tech-
nologies, Carlsbad, CA) and exposed to 1% oxygen tension
for 48 h. The resulting 3L of conditioned media was pro-
cessed for pMEX isolation using a preclearing centrifugation
step at 1,000g for 15min, followed by vacuum-assisted fil-
tration using a 0.2mM PES filter. The resulting solution was
then ultrafiltered using tangential flow filtration with a mo-
lecular weight cutoff PES membrane of 100 kDa. Once con-
centrated, the pMEX solution is then diafiltrated using PBS to
perform a buffer exchange using the same tangential flow
filtration cartridge. pMEX protein concentration was deter-
mined using DC assay (Bio-Rad, Hercules, CA), and size
distribution of vesicle diameter was determined using Nano-
Sight LM10HS (Malvern, Amesbury, MA).
Exosome uptake and proliferation
For uptake studies, pMEX were labeled with CellMask
Green (Thermo Fisher, Carlsbad, CA) according to manu-
facturer’s instructions. Negative controls consisted of an
equal volume of PBS that was processed with either PKH26
or CellMask Green according to manufacturer’s instruction.
SHYSY’s were plated into a six-well format tissue culture
plate at 15,000 cells/cm2 and allowed to sit down overnight
in 20% FBS in MEM-a, 1% l-glutamine, and 1%Pen-
Strep. The following morning, the cells were washed three
times with PBS before addition of OptiMEM without phenol
red with 1% l-glutamine containing labeled pMEX or an
equal volume of ‘‘labeled’’ PBS. One hour following ex-
posure to treatment conditions, cells were washed three
times with PBS and lifted with TrypLE for analysis via
fluorescent microscopy or flow cytometry (Attune NxT;
Thermo Fisher).
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For proliferation studies, SHYSY5Y’s were seeded at
9,000 cells/cm2 in a six-well format tissue grade plate, and
expanded in 20% FBS in MEM-a, 1% l-glutamine, and
1%Pen-Strep. SHYSY5Y’s were serum starved using Mini-
mum Essential Medium Eagle alpha with 1% l-glutamine
(Life Technologies) for 24 h after being washed three times
with PBS. Following 24 h of serum deprivation, fresh serum
media was placed on all cells with appropriate treatment
condition using a six-well format tissue culture plate. Cells
were incubated with pMEX then lifted with TrypLE. Cells
were then evaluated for proliferation rates using CCK-8
assay (colorimetric assay) or Edu-FITC assay (flow cyto-
metry) or nuclear staining with Hoechst 33342 (fluorescence
microscopy). For inhibitor studies, cells were exposed to
100mM of R-G-D-S peptide direct inhibitor of fibronectin
binding or 10mM of PHT427 (a pleckstrin homology domain,
small molecule inhibitor to AKT) with or without 100mg of
pMEX before mitotic assessment. For growth factor secretion
assessment, supernatants from SHSY5Y proliferation studies
(100mg pMEX vs. PBS control) were analyzed using Ray-
Biotech’s Q1 Growth Factor Quantibody array according to
manufacturer’s instructions. Proliferation studies were per-
formed three times to verify the reproducibility of the ob-
served results.
Electron microscopy
pMSC and PMEX samples (n= 3 biological replicates)
were fixed and dehydrated before scanning electron micros-
copy image acquisition with a Philips XL30 TMP (FEI
Company, Hillsboro, OR). Sputter Coater: Pelco Auto Sputter
Coater SC-7 (Ted Pella, Inc., Redding, CA). Transmission
electron microscopy images were acquired using Philips
CM120 Biotwin Lens, 9 (FEI Company, www.fei.com), with
2.0% uranyl acetate staining using facilities at Electron Mi-
croscopy Laboratory, School of Medicine, University of Ca-
lifornia at Davis.
Sample preparation for proteomics
pMSC and pMEX derived from three different biological
bone marrow aspirate donors were cultured, isolated, and
pelleted as previously described. Pellets were lysed with
25mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), 4% sodium dodecyl sulfate (SDS), and 1mM
dithiothreitol (DTT). Lysates were incubated at 95C for
5min then sonicated for 1min, and centrifugation at
14,000g for 15min. The supernatant was mixed with 8M
urea, 1mM DTT, and 25mM HEPES, pH 7.6, and trans-
ferred to a filtering unit with a 10 kDa cutoff (Nanosep;
Pall, Port Washington, NY), and centrifuged for 15min at
14,000g, followed by another addition of urea buffer and
centrifugation. Lysates were alkylated with 50mM in-
doleacetic acid (IAA), 8M urea, and 25mM HEPES for
10min and then centrifuged for 15min at 14,000g, followed
by two more additions of urea buffer and centrifugations.
Trypsin (Promega, Madison WI) was added to lysates at a
1:50 trypsin:protein ratio and incubated overnight at 37C.
The lysate containing filters were then centrifuged for
15min at 14,000g, followed by another centrifugation with
MilliQ water and the flow-through was collected [63].
Peptides from pMSC and pMEX were labeled with tandem
mass tag (TMT) TMT10 and TMT6, respectively, according
to manufacturer’s instructions (Thermo Fisher Scientific,
San Jose, CA). Peptides were then cleaned by a strata-X-C-
cartridge (Phenomenex, Torrance, CA) [63,64].
Proteomics on nLC-MS/MS on thermo
scientific LTQ Orbitrap Velos
Before analysis of pMEXs on LTQ-Orbitrap Velos (Ther-
mo Fisher, San Jose, CA), peptides were separated using the
Agilent 1200 nano-LC system. pMEX samples were trapped
on a Zorbax 300SB-C18 and separated on a NTCC-360/100-
5-153 (Nikkyo Technos, Tokyo, Japan) column with a gra-
dient of ‘‘A’’ (5% dimethyl sulfoxide, 0.1% formic acid) and
‘‘B’’ (90% acetonitrile, 5%DMSO, 0.1% formic acid), ranging
from 3% to 40% of ‘‘B’’ in 45min with a flow of 0.4mL/min.
LTQ-Orbitrap Velos was operated in a data-dependent man-
ner, which selected five precursors for the sequential frag-
mentation by collision-induced dissociation and higher energy
collisional dissociation, and subsequently analyzed by the
linear iontrap and orbitrap. The survey scan was completed
in the orbitrap at 30,000 resolution from 300 to 2,000m/z
with a maximum injection time of 500ms with automatic
gain control set to 1 · 106 ions. Generation of the higher
energy collisional dissociation fragmentation spectra, a max
ion injection time of 500ms, and an automatic gain control
of 5 · 104 were used before fragmentation at 37.5% nor-
malized collision energy. The normal mass range was used
for Fourier transform mass spectrometry MS2 spectra,
while centroiding the data at 7500 resolution. pMEX pep-
tides for collision-induced dissociation were accumulated
for a max ion injection time of 200ms and of automatic
gain control · 104, fragmented with 35% collision energy,
with the wideband activation on and activation of q 0.25
and an activation time of 10ms before analysis at the normal
scan rate and mass range in the linear iontrap. Precursors
were subsequently isolated with a width of 2 m/z and
positioned on the exclusion list for 60 s with both unas-
signed and single charge states being rejected from pre-
cursor selection.
Proteomic data analysis
Panther Pathway analysis was used to detect the number
of pathways detected in each sample and the number of
proteins of each pathway represented in each sample (www
.pantherdb.com). Ingenuity Pathway Analysis (IPA) soft-
ware was used to analyze enrichment for signaling path-
way proteins and putative functionality of proteins present
in and between each sample with a significance threshold
of 1% false discovery rate (Qiagen, Redwood City, CA
www.ingenuity.com). ClueGO software was used for gene
ontology and WikiPathway analysis of each sample to de-
termine functionality of broad classes of proteins (www
.ici.upmc.fr/cluego/). UniProt and IPA databases were also
used for protein classification schemes.
Statistical analyses
All statistical analyses were performed with GraphPad
Prism V6.07. Where appropriate, T tests or multiple T tests
with multiple testing correction were used with a false
discovery rate of 1%.
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Results
pMEX have canonical biophysical properties
and co-isolate with FBS contaminants
MSCs were isolated from human bone marrow purchased
from Lonza, as previously described. After, passage 3 cells
were assessed for expression of canonical MSC surface
markers using flow cytometry analysis. MSC were over 90%
for all three markers: CD73, CD90, and CD105 (Fig. 1A–C).
Nanoparticle tracking analysis determined that pMEX pos-
sess a canonical diameter size distribution, with a mean
diameter of 163 nm (n = 3 donors) (Fig. 1D). Transmission
electron microscopy in combination with contrast staining
demonstrated that pMEX have canonical exosome morphol-
ogy as previously reported (Fig. 1E). Analysis of pMEX’s
tandem mass spectrometry proteomic profile established that
they are packaged with 93 of the 100 most cited exosomal
markers according to the ExoCarta database (ExoCarta.org)
(Fig. 1F). Of all proteins detected across both pMSC and
pMEX, 7% of proteins were exclusively detected in the
pMEX samples (Fig. 1G).
pMSCs are initially passaged in expansion media up to
passage 6, followed by three stringent washes with PBS
before initiation of priming conditions (1% hypoxia and
serum deprivation) for 48 h, the resulting conditioned media
of which was harvested for pMEX. Ostensibly, such wash
steps and serum-free priming conditions should limit the
likelihood of co-isolation of bovine contaminants derived
from FBS. However, we calculated the sum total of peak
intensities for bovine proteins detected in both pMSC as
well as pMEX and determined that pMSC contained *3%
bovine material whereas pMEX contained a significantly
higher *18% FBS-associated proteins (n = 3 donors/group,
P < 0.01) (Fig. 1H). Therefore, better characterization of
FBS contaminants of exosomal preps is warranted, espe-
cially when extracellular vesicles are isolated from serum
containing isolation media, due to the increased risk of co-
isolation bovine contaminants.
pMEX contain elevated levels of specific
subclassifications of proteins with distinct
molecular functions
Although several studies have partially characterized the
contents of exosomes, it remains unclear if exosomes are
packaged with elevated levels of specific protein subtypes
[36,50,59,65–72]. To this end, we comprehensively evalu-
ated the proteomic profile of both pMSCs and pMEX based
FIG. 1. Flow cytometry,
HiRIEF LC-MS/MS pro-
teomics, nanoparticle tracking
analysis and electron micros-
copy analysis of pMSCs and
pMEXs. (A–C) Flow cyto-
metry analysis of MSC surface
marker expression usingmono-
clonal primary conjugated an-
tibodies against the canonical
MSC markers CD73, CD90,
and CD105. (D) Nanoparticle
tracking analysis determined
the size distribution of pMEX,
with a mean diameter of
163nm, red highlight= distri-
bution of events, black line=
median. (E)Transmission elec-
tronmicroscopy of pMEXwith
uranyl acetate negative stain-
ing (scale bar 200nm). (F)
HiRIEF LC-MS/MS proteo-
mic analysis identified 93 and
94 exosomalmarkers out of the
top 100 most cited in the Exo-
Carta database in pMSCs and
pMEXs, respectively. (G) Of
all, 6.7% proteins observed in
pMEX were exclusively de-
tected within pMEX, whereas
71.8% of all pMSCs proteins
were exclusively detected in
pMSCs. (H) FBS-derived pro-
teins were detected in both
pMSC and pMEX (n= 3/
group, FDR 1%). FBS, fetal
bovine serum; pMSCs, primed
mesenchymal stem cells.
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on protein localization and classification analysis using the
IPA database. We assessed both, protein area (ie, relative
mass) and the unique number of proteins associated with
each category. This method helped elucidate whether a
relatively large mass of a protein subtype is composed of
just a few highly abundant proteins, or conversely, com-
posed of numerous unique proteins present at low levels (ie,
relatively low mass).
pMEXs were packaged with proportionally elevated levels
of specific subclassifications of proteins compared with the
pMSCs from which they were derived. IPA demonstrated
that pMEX contained elevated levels of transporters, pep-
tidases, receptors, G-coupled receptors, and ion channels
compared with pMSC based on relative protein abundance
(n = 3 donors/group, P< 0.001) (Fig. 2A–D). Our analysis
further determined that pMEX contained a lower propor-
tion of proteins associated with transcription, kinase ac-
tivity, translation, and phosphatases compared with pMSC
based on relative abundance (n = 3 donors/group, P < 0.01)
(Fig. 2C). Of the proteins detected exclusively in pMEX,
we determined that transporter and G-coupled receptor
proteins were present in greater abundance than in pMSC
(n = 3 donors/group, P < 0.01) (Fig. 2D). Of the proteins
exclusively detected in pMSCs, enzymes and transcription-
associated proteins were present in higher percentages
(n = 3 donors/group, P < 0.01) (Fig. 2B). These data estab-
lish that pMEX are enriched for specific protein classifica-
tions, with >6· increase in relative abundance of receptors
and a *2· increase in transporter proteins compared with
pMSC.
Extracellular and plasma membrane proteins
are the most abundant protein classes
packed within pMEX
We analyzed our proteomics data to determine whether
pMEX are packaged with elevated levels of proteins as-
sociated with a specific subcellular localization compared
with their parental cell line, pMSCs. pMEX contained 4-fold
and 42-fold increase in receptor and extracellular proteins
than pMSC, respectively (n= 3 donors/group, P< 0.005)
(Fig. 3A–D). Of all specific extracellular pMEX proteins,
approximately half are ECM derived, however, these ECM
proteins comprise about *74.5% of all extracellular pMEX
proteins, based on relative abundance (Fig. 3E, F). Therefore,
a relatively small number of ECM proteins comprise
*35.8% of pMEXs total relative protein content.
pMEX are also packaged with 300% and 70% decrease of
cytoplasmic and nuclear localized proteins, respectively,
compared with pMSCs based on relative abundance (n= 3/
group, P< 0.005) (Fig. 3A–D). Although pMEXs contained a
similar fraction of specific cytoplasmic proteins as pMSCs, the
relative abundance of these cytoplasmic proteins was sub-
stantially less in pMEXs (n= 3 donors/group, P< 0.005)
(Fig. 3A–D). This indicates that the cytoplasmic proteins in the
exosomes were generally present at much lower levels (ie,
relative mass) than in pMSCs.We observed numerous proteins
that were detected exclusively either in pMSCs or pMEXs.
Of the proteins exclusively detected in pMEXs, there was 10·
and 3· increase in extracellular and plasma membrane-
associated proteins compared with proteins exclusively
FIG. 2. pMEXs are enriched for specific functional classifications of proteins. (A, C) IPA determined that pMEXs contain
elevated fractions of transporters, peptidases, receptors, G-coupled receptors, and ion channels compared with pMSCs.
pMEX contained lower fractions of transcription, kinase activity, translation, and phosphatase proteins compared with
pMSCs. Proteins exclusively detected in pMSCs (B) contained elevated fractions of enzymes and transcription-associated
proteins than proteins detected exclusively in pMEX. (D) Proteins exclusively detected in pMEX contained higher frac-
tions of transporters and G-coupled receptors. n = 3/group, FDR 1%. Red highlight = higher fraction in pMEX, blue high-
light = lower fraction in pMEX. IPA, Ingenuity Pathway Analysis.
MSC EXOSOMES’ FUNCTIONAL PROTEINS 5
detected in pMSC based on relative mass (n= 3 donors/
group, P< 0.005) (Fig. 3A–D). These data demonstrate
that pMEX contained higher fractions of both extracellular
and plasma membrane-associated proteins compared with
pMSCs.
pMEX are packaged with ECM proteins
associated with proliferation
Studies have established that MSCs have mitogenic
properties. Therefore, we examined the proteomic profile
of pMEX for genes associated with either the induction or
inhibition of cellular proliferation. IPA demonstrated that
pMEX are packaged with *700 proliferation-associated
proteins, of which 689 were associated with increased pro-
liferation (Fig. 4). Based solely on the number of unique
individual proteins detected, cytoplasmic proteins were the
largest represented protein class in pMEX (Supplementary
Fig. S1). However, based on relative abundance, extracel-
lular proteins were the most abundant class and accounted
for 43% of the total proliferation-associated protein content
detected in pMEX (Supplementary Fig. S1A, B). Enrichment
of mitogenic extracellular proteins suggests that pMEXs pro-
liferative properties may be mediated by such proteins.
Extracellular protein fibronectin mediates
pMEXs mitogenic properties
Next, we proceeded to investigate whether the abundant
extracellular-associated proteins packaged into pMEX may
mediate some of their functional properties. The observation of
numerous proliferation-associated proteins detected in pMEX,
many of which were extracellular in nature, led us to investi-
gate the mitogenic capacity of pMEX. We determined that
fluorescently labeled pMEX (100mg) are taken up by the
neuroblast-like cell line, SHSY5Y’s, within 1 h of exposure by
fluorescent microscopy and flow cytometry analysis (n= 3
replicates/group, P< 0.005) (Fig. 5A–C). Treatment with
100mg pMEX significantly induced proliferation of SHYSY5
cells compared with vehicle (PBS)-treated controls, as deter-
mined by both CCK8 absorbance as well as image evaluation
of Hoechst 33342 nuclear-stained cells (n= 3 replicates/group,
P< 0.005) (Fig. 5D–F). Using the more sensitive Edu prolif-
eration assay, we established that pMEX induced proliferation
FIG. 3. pMEXs are en-
riched for extracellular and
plasma membrane proteins.
(A) Distribution of all proteins
across cellular sublocalization
classes in pMSC and (B) pro-
teins exclusively detected in
pMSC according to IPA. (C)
Distribution of all proteins
across cellular sublocalization
classes in pMEX, and (D)
proteins exclusively detected
in pMEX according to IPA.
(E) Fraction of pMEX unique
extracellular proteins that were
either associated with ECM or
secretory proteins. (F) Fraction
of pMEX proteins abundance
associated either with ECM or
secretory proteins. n=3/group,
FDR 1%. ECM, extracellular
matrix.
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FIG. 4. pMEXs are packaged
with proliferation-associated
proteins. IPA of pMEXs pro-
teomic profile established pres-
ence of 701 mitogenic proteins.
Relative abundance of each
protein is indicated by the depth
of shading of each node. Pink
edge lines represent proteins
known to induce proliferation,
green edge lines represent pro-
teins known to inhibit prolifer-
ation, n= 3, FDR1%.
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in a dose-dependent manner as evaluated via flow cytometry
(n= 3 replicates/group, P< 0.005) (Fig. 5G, H).
Since extracellular proteins were the most abundant class of
proliferative proteins in pMEX, we proceeded to investigate
whether secreted proteins mediated pMEXs mitogenic proper-
ties. Fibronectinwas determined to be themost overall abundant
protein in pMEX, which provided the rationale for testing the
inhibition of this pathway to determine if fibronectin signaling
mediates pMEXs mitogenic properties. We used a specific in-
hibitor of AKT signaling (PHT427), which binds the pleckstrin
homology domain of AKT, blocking its ability to phosphorylate
proteins downstream in the fibronectin signaling cascade. Our
data demonstrated that AKT inhibition (10mM) significantly
attenuated pMEX-induced proliferation in SHYSY5Y’s (n=3
replicates/group, P< 0.0005) (Fig. 5I, J). To validate the in-
volvement of fibronectin signaling in themitogenic properties of
pMEX, we next used a competitive binding peptide inhibitor of
fibronectin signaling (R-G-D-S) concurrent with 100mg pMEX
FIG. 5. pMEX are readily taken
up by cells and induce proliferation.
(A) 100mg pMEX were fluores-
cently labeled with the lipophilic
dye, PKH26, washed, and then ex-
posed to SHSY5Y cells for 1 h, and
evaluated via fluorescent micros-
copy with a 4· objective. SHSY5Y
cells costained with Hoechst 33342.
(B, C) Quantification of pMEX up-
take by SHSY5Y’s was determined
using flow cytometry analysis of
SHSY5Y exposed to 100mg Cell-
Mask Green fluorescent labeled
pMEX for 1 h, compared to Cell-
Mask Green ‘‘labeled’’ PBS con-
trols. (D–F) Treatment of serum-
deprived SHSY5Y cells with 100mg
pMEX for 18h induced proliferation
as determined by CCK8 colori-
metric assay followed by fluores-
cent microscopy of Hoechst 33342-
stained cells. (G, H) Following
18 h serum deprivation, SHSY5Y’s
were treated with 100 mg pMEX
and assessed for proliferation 18 h
posttreatment with flow cytometry
analysis of FITC-labeled Edu com-
pared with vehicle (PBS) controls.
(I, J) SHSY5Y’s were treated with
100mg pMEX or vehicle controls
(PBS), in the presence or absence of
10mM AKT-specific inhibitor
(PHT427) and proliferation was
evaluated using Edu-FITC assay.
(K, L) SHSY5Y’s were treated with
100mg pMEX or vehicle control
(PBS), in the presence or absence of
100mM R-G-D-S peptide inhibitor
and proliferation was assessed using
Edu-FITC assay. All proliferation
studies were performed three times
to verify reproducibility n= 3, T test
analysis was used to test for sig-
nificance, *P< 0.05, **P< 0.01,
***P< 0.005. PBS, phosphate-
buffered saline.
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treatment in SHSY5Y cells. The R-G-D-S fibronectin inhibitor
(100mM) attenuated the mitogenic capacity of 100mg pMEX
treatment by 22% in the SHSY5Y cell line (n= 3 replicates/
group, P<0.05) (Fig. 5K, L). Collectively, these data demon-
strated that pMEX are packaged with extracellular proteins
which, in part, mediated their ability to potentiate cellular pro-
liferation in a fibronectin-dependent manner. All proliferation
studies were performed three times to verify reproducibility.
pMEX potentiated secretion of growth factors
by neuroblast-like cells
Next, we investigated whether 100mg pMEX treatment
modulated the secretory profile of SHSY5Y cells. We used a
multiplexed sandwich ELISA cytokine array (Quantibody)
(Supplementary Fig. S2) to quantitatively assess growth and
trophic factor secretion of SHSY5Y’s 24 h post-pMEX
(100 mg) treatment. Multiplexed sandwich ELISA cytokine
array analysis determined that pMEX treatment increased
secretion of 14 factors with well-established proliferative
and trophic properties (n = 4/group, P< 0.05–P < 0.0005)
(Fig. 6A, B). These factors have been established as medi-
ators of cellular proliferation and their increased secretion
positively correlated with pMEXs mitogenic properties.
Discussion
There is growing interest in MSC-derived exosomes both
as a means to elucidate MSCs’ mechanisms of action, and
as potential standalone monotherapy. However, little is un-
derstood about the physiology of exosomes derived from
MSCs. One outstanding question has been which factors are
enriched in MSC-derived exosomes and what functional
properties do they convey when their biogenesis is potenti-
ated under physiological conditions [18,19,41–48,54,73–75].
In this study, we determined that the most abundant proteins
detected in pMEXs were of an extracellular origin. We also
observed a several fold enrichment of receptor and trans-
porter proteins in pMEXs compared with the MSC parental
lines from which they were derived. These data indicate that
the most abundant exosomal proteins are extracellular and
plasma membrane associated, which may have important
implications for their observed functional properties.
We determined that pMEXs were packaged with numerous
extracellular and plasma membrane-associated proteins pre-
dicted to induce proliferation. We functionally validated the
mitogenic properties of pMEX using a cell line with neuronal
properties (SHSY5Y), an indication that the specific proteins
packaged into exosomes are predictive to some degree of
their physiological properties. Interestingly, we found over
400 proteins detected exclusively in exosomes, although the
lack of detection of these proteins in the MSCs may be at-
tributable to masking effects due to their more complex cel-
lular lysate. However, it is feasible that at least a subset of
these proteins is expressed exclusively for secretion into
exosomes. To date, most published reports of the functional
properties of MSC-derived exosomes have isolated extracel-
lular vesicles from canonical MSC culture media and oxygen
tension. There remains the possibility that such conditions
induce cellular signaling cascades that induce differences in
the secretome of MSCs compared with MSCs cultured under
conditions that more closely mimic those experienced by
MSCs postadministration in vivo. Hence, further investiga-
tion into the potential differences between exosomes isolated
under such different conditions may be informative to the
field, both in terms of their proteomic packaging as well as
their pleotropic functional properties.
Conclusion
Taken together, the data from this investigation suggest
that the packaging of exosomes with proteins is not per-
formed in a stochastic manner, as we observed substantial
enrichment of specific proteins and protein classes com-
pared with their parental cell line. Further work is warranted
to elucidate the mechanisms by which cells regulate protein
packaging in exosomes. Although several preclinical studies
support the application of MSC exosomes as a novel ther-
apeutic platform, elucidating the mechanisms of action is
critical in advancing this technology.
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